{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:47:47Z","timestamp":1787032067719,"version":"build-2736575974"},"reference-count":23,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.5582\/ddt.2025.01136","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:09:39Z","timestamp":1781302179000},"page":"211-220","source":"Crossref","is-referenced-by-count":1,"title":["Low rate of pharmacists accessing renal function laboratory values: A cross-sectional study using electronic medical records of a Japanese community pharmacy"],"prefix":"10.5582","volume":"20","author":[{"given":"Shingo","family":"Kondo","sequence":"first","affiliation":[{"name":"Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, Tokyo, Japan."},{"name":"Keio University Community Pharmacy, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Maese","sequence":"additional","affiliation":[{"name":"Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, Tokyo, Japan."},{"name":"Keio University Community Pharmacy, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, Tokyo, Japan."},{"name":"Keio University Community Pharmacy, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Iwata","sequence":"additional","affiliation":[{"name":"Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, Tokyo, Japan."},{"name":"Keio University Community Pharmacy, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, Tokyo, Japan."},{"name":"Keio University Community Pharmacy, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yamaura","sequence":"additional","affiliation":[{"name":"Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, Tokyo, Japan."},{"name":"Keio University Community Pharmacy, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review. JAMA. 2019; 322:1294-1304.","DOI":"10.1001\/jama.2019.14745"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O&apos;Callaghan CA, Lasserson DS, Hobbs FD. Global prevalence of chronic kidney disease \u2013 A systematic review and meta-analysis. PLOS One. 2016; 11:e0158765.","DOI":"10.1371\/journal.pone.0158765"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai CY, Floyd T, Al-Aly Z. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018; 94:567-581.","DOI":"10.1016\/j.kint.2018.04.011"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S. Slower decline of glomerular filtration rate in the Japanese general population: A longitudinal 10-year follow-up study. Hypertens Res. 2008; 31:433-441.","DOI":"10.1291\/hypres.31.433"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Imai E, Horio M, Iseki K, <i>et al.<\/i> Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007; 11:156-163.","DOI":"10.1007\/s10157-007-0463-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zafar R, Rehman IU, Shah Y, Ali Z, Ming LC, Khan TM. Knowledge, attitude and perceptions of pharmacists regarding renal dose adjustment among chronic kidney disease patients in Pakistan. J Pharm Policy Pract. 2023; 16:102.","DOI":"10.1186\/s40545-023-00606-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wada R, Takeuchi J, Nakamura T, Sonoyama T, Kosaka S, Matsumoto C, Sakuma M, Ohta Y, Morimoto T. Clinical decision support system with renal dose adjustment did not improve subsequent renal and hepatic function among inpatients: The Japan adverse drug event study. Appl Clin Inform. 2020; 11:846-856.","DOI":"10.1055\/s-0040-1721056"},{"key":"8","unstructured":"8. Kappel J, Calissi P. Nephrology: 3. Safe drug prescribing for patients with renal insufficiency. CMAJ. 2002; 166:473-477."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kondo Y, Ishitsuka Y, Shigemori E, Irikura M, Kadowaki D, Hirata S, Maemura T, Irie T. Awareness and current implementation of drug dosage adjustment by pharmacists in patients with chronic kidney disease in Japan: A web-based survey. BMC Health Serv Res. 2014; 14:615.","DOI":"10.1186\/s12913-014-0615-0"},{"key":"10","unstructured":"10. The Japanese Society of Nephrology and Pharmacotherapy. Dosage recommendations for drugs that require the most attention in renal impairment. 37th ed. 2024. <i>https:\/\/www.jsnp.org\/files\/dosage_recommendations_37.pdf<\/i> (Accessed March 31, 2026)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Oni L, Hawcutt DB, Turner MA, Beresford MW, McWilliam S, Barton C, Park BK, Murray P, Wilm B, Copple I, Floyd R, Peak M, Sharma A, Antoine DJ. Optimising the use of medicines to reduce acute kidney injury in children and babies. Pharmacol Ther. 2017; 174:55-62.","DOI":"10.1016\/j.pharmthera.2017.02.018"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Har\u0119\u017clak T, Religioni U, Szyma\u0144ski FM, Hering D, Bara\u0144ska A, Neumann-Podczaska A, Allan M, Merks P. Drug Interactions Affecting Kidney Function: Beware of Health Threats from Triple Whammy. Adv Ther. 2022; 39:140-147.","DOI":"10.1007\/s12325-021-01939-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fujii M, Ohno Y, Ikeda A, Godai K, Li Y, Nakamura Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kabayama M. Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: Analysis using the National Database of Health Checkups in Japan. Hypertens Res. 2023; 46:1075-1089.","DOI":"10.1038\/s41440-023-01185-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nitta K, Goto S, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, Nakai S, Wada A, Hamano T, Hoshino J, Joki N, Abe M, Yamamoto K, Nakamoto H. Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality. Ren Replace Ther. 2020; 6:41.","DOI":"10.1186\/s41100-020-00286-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hosohata K, Inada A, Oyama S, Furushima D, Yamada H, Iwanaga K. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach. J Clin Pharm Ther. 2019; 44:49-53.","DOI":"10.1111\/jcpt.12748"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yoshimura N, Iidaka T, Horii C, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T, Tanaka S. Trends in osteoporosis prevalence over a 10 year period in Japan: The ROAD study 2005\u20132015. J Bone Miner Metab. 2022; 40:829-838.","DOI":"10.1007\/s00774-022-01352-4"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kondo Y, Shikamura Y, Suzuki M, Takahashi M, Kawakami E, Hashiba H, Miyazaki C. Renal function ascertainment rate of patients at community pharmacies in Japan: a national survey. Ren Replace Ther. 2025; 11:22.","DOI":"10.1186\/s41100-025-00618-7"},{"key":"18","unstructured":"18. Moffet HH, Parker MM, Sarkar U, Schillinger D, Fernandez A, Adler NE, Adams AS, Karter AJ. Adherence to laboratory test requests by patients with diabetes: the Diabetes Study of Northern California (DISTANCE). Am J Manag Care. 2011; 17:339-344."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Imai S, Momo K, Kashiwagi H, Miyai T, Sugawara M, Takekuma Y. A cross-sectional exploratory survey on occurrence of triple-whammy prescription pattern in Japan. Int J Clin Pharm. 2020; 42:1369-1373.","DOI":"10.1007\/s11096-020-01088-z"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kunitsu Y, Hira D, Morikochi A, Ueda T, Isono T, Morita S, Terada T. Time until onset of acute kidney injury by combination therapy with &quot;Triple Whammy&quot; drugs obtained from Japanese Adverse Drug Event Report database. PLOS One. 2022; 17:e0263682.","DOI":"10.1371\/journal.pone.0263682"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013; 346:e8525.","DOI":"10.1136\/bmj.e8525"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kestin R, Howe A, Moose J, Marciniak MW, Rhodes LA. Impact of health information exchange access on medication management recommendations in a community-based pharmacy setting. J Am Pharm Assoc (2003). 2024; 64:102104.","DOI":"10.1016\/j.japh.2024.102104"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Narisue M, Sugimoto Y, Hirano F, Nakatsukasa R, Miyazaki K, Otsubo T, Nakashima M, Hirata S. Survey of prescriptions for triple whammy drug combinations with vitamin D as a possible fourth whammy. Int J Clin Pharmacol Ther. 2023; 61:8-15.","DOI":"10.5414\/CP204234"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/3\/20_2025.01136\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:26:32Z","timestamp":1784348792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/3\/20_2025.01136\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01136","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"2025.01136"}}